The tumor-infiltrating lymphocyte (TIL) cell therapy OBX-115 produced responses with no dose-limiting toxicities (DLTs) in heavily pretreated patients with advanced or metastatic melanoma whose who had progressed on anti–PD-1 and anti–CTLA-4 therapy with disease that was primary-resistant to immune checkpoint inhibitor (ICI) therapy, according to topline data from a phase 1 trial (NCT05470283).
Clinical Trials
BMS’ LAG-3 RELATIVITY theory fails futility test
Bristol-Myers Squibb has abandoned a bid to extend the indications of its combination of PD-1 inhibitor Opdivo and LAG-3 inhibitor relatlimab into colorectal cancer after it failed the phase 3 RELATIVITY-123 trial.
mRNA-4157 Plus Pembrolizumab Continues to Improve RFS in High-Risk Melanoma
Findings from 3-year follow-up of KEYNOTE-942/mRNA-4157-P201 show that the cancer vaccine mRNA-4157 plus pembrolizumab reduced the risk of recurrence or death in patients with stage III/IV melanoma following resection.
Study Results Find Different Mechanisms of Action in 2 Immune Checkpoint Inhibitor Regimens
The differences between the regimens, anti-PD1/CTLA-4 and anti-PD1/LAG-3, can be used to optimize outcomes for patients with melanoma, particularly in those who develop drug resistance.